0.63
0.63 (0%)
As of Feb 14, 2025
Bio-Path Holdings Inc [BPTH]
Source:
Company Overview
Bio-path Holdings, Inc. is a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease.
| Country | United States |
| Headquarters | bellaire, texas |
| Phone Number | (832) 742-1357 |
| Industry | manufacturing |
| CEO | President |
| Website | www.biopathholdings.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-12 |
| Net Income | $-9.9 |
| Net Cash | $0.1 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -278.6% |
| Profit as % of Stockholder Equity | -6,424.7% |
Management Effectiveness
| Return on Equity | -6,424.7% |
| Return on Assets | -254.8% |
| Turnover Ratio | |
| EBITA | $-12 |
Balance Sheet and Cash Flow Measures
| Total Assets | $3.9 |
| Total Liabilities | $3.7 |
| Operating Cash Flow | $-10.6 |
| Investing Cash Flow | |
| Financing Cash Flow | $10.7 |
